Market research
BCLI Brainstorm Cell Therapeutics Inc
PINK USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 17
- Dividend yield
- Not available
- Beta
- 0.26
Profile
Instrument facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 17
- Dividend yield
- Not available
- Beta
- 0.26
About
About Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of Alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Research context
Brainstorm Cell Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the BCLI discussion.
5 years, 6 months ago
Brainstorm Cell Therapeutics Inc is currently in a long term downtrend where the price is trading 40.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Brainstorm Cell Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 53.6% to $-12M since the same quarter in the previous year.
Finally, its free cash flow fell by 115.5% to $-8M since the same quarter in the previous year.
Based on the above factors, Brainstorm Cell Therapeutics Inc gets an overall score of 1/5.